Organovo & Viscient Biosciences Collaborate for 3D Bioprinting in Liver Disease Research

Earlier this month, both Organovo and Viscient Biosciences announced their intent to collaborate on research for further studies into liver disease. There have been many interesting stories about Organovo and their advances—from promises regarding 3D printed kidney and liver tissue for pharmaceutical testing to new data about extended survival and function in animal test subjects.

This latest partnership of Organovo’s will of course continue to build on all the research they have in place, much of which is centered around bioprinting. Viscient’s interests lie in research surrounding drug discovery efforts for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

“We continue to have excellent traction with a wide range of biopharmaceutical companies in evaluating our tissue systems to facilitate the discovery and development of novel drug candidates to treat liver disease. Our 3D disease models have the unique capability to demonstrate drug mechanisms of action and efficacy in a setting that closely mimics human livers,” said Taylor J. Crouch, CEO, Organovo.

“We’re proud to collaborate with Viscient’s talented team as they have a strong understanding of our expertise.  Our aim is to establish a custom platform that will support high-value drug profiling, and ultimately move our collaboration into a steady-state relationship.”

Such research is extremely important to the public, as around 100 million adults living in the US currently suffer from NAFLD, while an additional 20 million are living with NASH.

NAFLD is associated with inflammation, and an overload of fatty tissue in the liver. This important organ can be damaged, with lifelong consequences. As they collaborate, the hope is that Organovo and Viscient Biosciences will be able to create progressive and therapeutic treatments for NAFLD. Both conditions can lead to extremely serious illness, in the form of cirrhosis and cancer—and NASH is known as the second leading cause of liver transplants.

Organovo’s research is leading to many breakthroughs in studies regarding drug discovery, one of the greatest benefits of bioprinting. ExVive™ human liver and kidney tissues are used in the following:

• Compound screening in disease models
• Toxicology
• Target and marker discovery/validation
• Other types of drug testing

“Viscient is a strong believer in unlocking the power of 3D bioprinting to bring cures and treatments to patients with few options today,” said Keith Murphy, CEO, Viscient Biosciences. “In our pursuit of breakthrough therapies in important areas of medicine, we’re eager to tap into novel, complex and more accurate disease models. Organovo’s technology provides the potential for valuable and unprecedented insights as we target new drugs in areas of unmet medical need and strong commercial potential.

“Viscient’s plan goes arm and arm with Organovo,” Murphy said. “Viscient is going to be one of Organovo’s pharma customers.”

Headquartered in San Diego, Viscient is heavily involved in using 3D printing to make strides in drug development—and in fact, the company is comprised of former Organovo and Ardea Biosciences scientists and entrepreneurs. Find out more about them here.

Discuss this article and other 3D printing topics at 3DPrintBoard.com or share your thoughts below. 

[Sources / Images: XConomy: Globe NewsWire]